Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note issued to investors on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently weighed in on the company. Cantor Fitzgerald lifted their target price on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. HC Wainwright initiated coverage on Vanda Pharmaceuticals in a report on Thursday, October 31st. They set a “buy” rating and a $18.00 price target on the stock.

Vanda Pharmaceuticals Price Performance

NASDAQ VNDA traded up $0.17 on Friday, hitting $5.19. 831,245 shares of the company traded hands, compared to its average volume of 776,870. The business’s 50 day moving average price is $4.79 and its 200-day moving average price is $5.24. Vanda Pharmaceuticals has a 52-week low of $3.30 and a 52-week high of $6.75.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Acadian Asset Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 4.7% in the first quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock worth $9,740,000 after purchasing an additional 107,203 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Vanda Pharmaceuticals by 17.0% in the second quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock worth $11,379,000 after purchasing an additional 292,172 shares during the last quarter. Nantahala Capital Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 57.3% in the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock worth $9,003,000 after purchasing an additional 580,265 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Vanda Pharmaceuticals by 7.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 780,933 shares of the biopharmaceutical company’s stock worth $3,663,000 after purchasing an additional 55,567 shares during the last quarter. Finally, Profit Investment Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 159.3% in the second quarter. Profit Investment Management LLC now owns 571,324 shares of the biopharmaceutical company’s stock worth $3,228,000 after purchasing an additional 351,000 shares during the last quarter. 88.14% of the stock is owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.